阿托伐他汀钙序贯治疗丙氨酸转氨酶升高患者的效果观察被引量：1

在线阅读下载PDF

导出

摘要目的探讨阿托伐他汀钙序贯治疗(患者均在经皮冠状动脉介入治疗术前24 h内给予阿托伐他汀钙80 mg,再以40 mg/d维持1个月)在丙氨酸转氨酶(ALT)升高患者应用的安全性和有效性。方法选择收治的急性冠脉综合征(ACS)患者96例,收集临床资料,根据入院用药前血清ALT的水平分组,ALT正常并接受阿托伐他汀序贯治疗的为A组;ALT升高<3倍正常值上限(ULN)并接受阿托伐他汀序贯治疗的为B组,分别在入院用药后7、30 d测定肝肾功能、肌酶、血脂指标;比较两组用药7 d后肝功能及用药后30 d降脂疗效。结果治疗7 d后,A组与B组比较,ALT>3ULN的发生率,差异无统计学意义(2=0.07,P=0.79);两组用药后30 d血脂比较,总胆固醇、三酰甘油、低密度脂蛋白、高密度脂蛋白差异无统计学意义(P>0.05)。结论 ALT轻度升高的ACS患者早期使用阿托伐他汀钙序贯治疗安全有效。

作者王欣欣陈金国刘俊张军沈童童

机构地区安徽省滁州市第一人民医院心血管内科一区

出处《广东医学》 CAS CSCD 北大核心 2014年第12期1941-1943,共3页 Guangdong Medical Journal

关键词阿托伐他汀钙序贯疗法丙氨酸转氨酶不良反应

分类号 R512.6 [医药卫生—内科学]

作者简介安徽医科大学2011级在读硕士研究生通信作者。E—mail：chenjinguo2011@126．com

引文网络
相关文献

参考文献16

1BELL R M, YELLON D M. Atorvastatin, administered at the on- set of reperfusion, and independent of lipid lowering, protects the myocardium by up - regulating a pro - survival pathway[J]. J Am Coil Cardiol, 2003, 41 (3) : 508 -515.
2MENSAH K, MOCANU M M, YELLON D M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chro- mosome ten? [J]. J Am Coil Cardiol, 2005, 45(8) : 1287 - 1291.
3BALLANTYNE C M, RAICHLEN J S, NICHOLLS S J, et al. Effect of rosuvastatin therapy on coronaryartery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravaseularultrasound - derivedcoronary atherom- aburden[ J ]. Circulation, 2008, 117 (19) : 2458 - 2466.
4DI SCIASCIO G, PATTI G, PASCERI V, et al. Efficacy of atorv-astatin reload in patients on chronic statin therapy undergoing per- cutaneous coronary intervention: results of the ARMYDA - RE- CAPTURE ( Atorvastatin for Reduction of Myocardial during Angio- plasty) Randomized Trial[J]. J Am Coil Cardiol, 2009, 54(6) : 558 - 565.
5BRIGUORI C, VISCONTI G, FOCACCIO A, et al. Novel approa- ches for preventing or limiting events (Naples) U trial : impact of a single high loading dose of atorvastation on periprocedural myocardi- al infarction[J]. J Am Coll Cardiol, 2009, 54(23) : 2175 -2163.
6罗育坤,林朝贵,范林,陈昭阳,董现锋,陈良龙.阿托伐他汀序贯治疗择期经皮冠状动脉介入患者的有效性和安全性[J].中国动脉硬化杂志,2012,20(9):824-828. 被引量：20
7LAROSA J C, GRUNDY S M, WATERS D D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary dis- ease[J]. NEnglJMed, 2005, 352(14): 1425 -1435.
8WATERS D D. Safety of high - dose atorvastatin therapy[J]. Am J Cardiol, 2005, 96(5A) : 69F-75F.
9CHALASANI N, ALJADHEY H, KESTERSON J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepato- toxieity[J]. Gastroenterology, 2004, 126(5) : 1287 - 1292.
10LIU H L, YANG Y, YANG S L, et al. Administration of a load- ing dose of atorvastatin before pereutaneous coronary interventionprevents inflammation and reduces myocardial injury in STEMI pa- tients: A randomized clinical study [ J]. Clin Ther, 2013, 35 (3) : 261 -272.